Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review ; volume:36 ; number:1 ; day:27 ; month:5 ; year:2024 ; pages:1-11 ; date:12.2024
Journal of the Egyptian National Cancer Institute / Egyptian National Cancer Institute; 36, Heft 1 (27.5.2024), 1-11, 12.2024
- Creator
-
Mulyadi, Rahmad
Hasan, Irsan
Sidipratomo, Prijo
Putri, Pungky Permata
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43046-024-00224-4
- URN
-
urn:nbn:de:101:1-2407012112388.267521694261
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mulyadi, Rahmad
- Hasan, Irsan
- Sidipratomo, Prijo
- Putri, Pungky Permata
- SpringerLink (Online service)
Other Objects (12)
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Combined Transarterial Chemoembolization and Percutaneous Ablation: A Single-Center Experience
Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Combined Transarterial Chemoembolization and Percutaneous Ablation: A Single-Center Experience
Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
Transarterial Chemoembolization – Status Quo in Germany
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Combined Transarterial Chemoembolization and Percutaneous Ablation: A Single-Center Experience